No Data
No Data
Eddy Pharmaceuticals (688488.SH) reported first-quarter results with a net loss of 13.6069 million yuan
Eddy Pharmaceuticals (688488.SH) released its report for the first quarter of 2024. The company achieved operating revenue during the reporting period...
Insiders Are the Top Stockholders in Jiangsu Aidea Pharmaceutical Co., Ltd. (SHSE:688488), and the Recent 12% Drop Might Have Disappointed Them
Key Insights Insiders appear to have a vested interest in Jiangsu Aidea Pharmaceutical's growth, as seen by their sizeable ownership 53% of the business is held by the top 4 shareholders Institut
Eddy Pharmaceuticals (688488.SH) is planning a major asset restructuring to acquire 31.16% of Nanda Pharmaceutical's shares to take control of it
Eddy Pharmaceutical (688488.SH) announced that recently, the company and Nanjing Nanda Pharmaceutical Co., Ltd. (hereinafter referred to as...
Eddy Pharmaceuticals (688488.SH): Net loss of 76.0695 million yuan in 2023
Gelonghui, April 15 | Eddy Pharmaceutical (688488.SH) released its 2023 annual report. During the reporting period, it achieved operating income of 411 million yuan, an increase of 68.44% over the previous year; net profit attributable to shareholders of listed companies - 76.695 million yuan; and basic earnings per share - 0.18 yuan.
What Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) 27% Share Price Gain Is Not Telling You
Those holding Jiangsu Aidea Pharmaceutical Co., Ltd. (SHSE:688488) shares would be relieved that the share price has rebounded 27% in the last thirty days, but it needs to keep going to repair the rec
Eddy Pharmaceuticals (688488.SH): Pre-loss of 63 million yuan to 90 million yuan in 2023
Gelonghui, January 30丨Eddy Pharmaceutical (688488.SH) announced its 2023 annual results forecast. According to preliminary estimates by the finance department, the company's annual revenue for 2023 is expected to be about 416.585 million yuan, an increase of about 172.3612 million yuan compared with the previous year, an increase of about 70.58% over the previous year. Among them, revenue from innovative anti-HIV drugs is expected to be 73.5788 million yuan, an increase of 119.67% year on year. Revenue from crude human protein products is estimated to be 262.20.29 million yuan, an increase of 82.82% year on year; Realize your return for the year 2023
No Data